Migraine Clinical Study

Last updated: September 11, 2023
Sponsor: Biohaven Pharmaceuticals
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

TX317052
  • Ages 18-100
  • All Genders

Study Summary

A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age of onset of migraines prior to 50 years of age
  • Migraine attacks, on average, lasting 4 - 72 hours if untreated
  • Per subject report, at least 15 headache days per month, at lest 8 migraine days per month, and at least 1 headache-free day per month within the last 3 months prior to the Screening Visit
  • Ability to distinguish migraine attacks from tension/cluster headaches
  • Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.

Exclusion

Exclusion Criteria:

  • Subject with a history of HIV disease
  • Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening
  • Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
  • Subjects with major depressive episode or anxiety disorder which require more than 1 daily medication for each disorder or subjects with a major depressive episode within the last 12 months. Medications to treat major depressive disorder or an anxiety disorder must have been at a stable dose for at least 3 months prior to the Screening Visit.
  • Subjects with active chronic pain syndromes, other pain syndromes (including trigeminal neuralgia), psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion interfere with study assessments of safety or efficacy.
  • Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease or condition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causes malabsorption.
  • Body mass index > 33 kg/m2
  • History of gallstones or cholecystectomy.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • Condition: Migraine Clinical Study
  • Clinical Trial Identifier: NCT04804033
  • Sponsor: Biohaven Pharmaceuticals

Connect with a study center

  • AMR Kansas City (formerly Center for Pharmaceutical Research)

    Kansas City, Missouri 64114
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.